RBC Capital maintains Gilead Sciences at Sector Perform, raises price target to $131 from $126

What happened

RBC Capital kept its Sector Perform rating on Gilead Sciences and raised its price target to $131 from $126, a 4.0% increase. That target implies a 20.9% downside from the October 29 close of $165.61.

Confirmed

Global impact / market context

A higher target still sits far below the current share price, so RBC sees the stock as fully valued rather than cheap. The unchanged Sector Perform rating tells investors the firm expects the shares to track the broader market, not beat it.

Analyst inference

Other recent analyst targets on Gilead range from $126 to $200, with several firms carrying Buy or Overweight ratings. RBC's target is the lowest of that group, placing it at the cautious end of current analyst views.

Analyst inference

What to watch

1. Five recent analyst notes on Gilead show price targets spanning $126 to $200, so target changes from other firms could shift the range investors compare against. Confirmed
2. Watch whether RBC changes its Sector Perform rating, which means it expects market-like returns, since a rating change would carry more weight than a target adjustment. Proposed
3. Track Gilead's upcoming results and guidance, because stronger revenue or profit could support higher targets and explain the gap to the $165.61 close. Analyst inference

Evidence

• Original source link unavailable